Cardiomyopathy due to ingestion of Adderall.
A patient is described who developed cardiomyopathy after receiving a therapeutic course of dextroamphetamine/amphetamine. The patient's cardiac function deteriorated to the point of heart failure, necessitating a heart transplantation. Cardiomyopathy associated with amphetamine use is a serious and potentially lethal condition. With early diagnosis, identification of the cause, and treatment, cardiomyopathy may be reversible. The dangers of therapeutic use of amphetamines are discussed, as well as problems and assumptions associated with U.S. Food and Drug Administration monitoring and removal from the market of harmful substances.
Marks
Donald H
DH
Department of Medicine, Cooper Green Mercy Hospital, Birmingham, Alabama, USA. DHMarks@Yahoo.com
D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D000662:Amphetamines / Q000009:adverse effects*; D009202:Cardiomyopathies / Q000139:chemically induced*; D000697:Central Nervous System Stimulants / Q000009:adverse effects*; D006333:Heart Failure / Q000139:chemically induced; D016027:Heart Transplantation; D006801:Humans; D008297:Male; D014481:United States; D014486:United States Food and Drug Administration
C090411:Adderall; D000662:Amphetamines; D000697:Central Nervous System Stimulants